A Study to Investigate the Effect of LY4086940 Versus Placebo in Participants With Obesity or Overweight and Without Type 2 Diabetes

Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-75
SponsorEli Lilly and Company

About this trial

The purpose of this study, performed under the master protocol W8M-MC- CWMM (NCT06143956), is to evaluate the efficacy and safety of LY4086940 compared with placebo in participants without type 2 diabetes who have obesity or who have overweight with a weight-related health condition.

Participation in the study will last about 58 weeks.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Meet inclusion criteria under Master Protocol CWMM (NCT06143956)

Disqualifiers

Have any prior diagnosis of type 2 diabetes, type 1 diabetes, or rare forms of diabetes mellitus, except gestational diabetes

Have a laboratory value suggestive of diabetes

acute myocardial infarction

cerebrovascular accident (stroke)

Trial design

Design model

Parallel

Treatments tested in this trial

  • LY4086940

    Drug

    Administered orally

  • Placebo

    Drug

    Administered orally

Treatment groups

460 Participants
are divided into 10 treatment groups

10

Treatment groups

See each treatment group below.

Group A: LY4086940 Dose 1Experimental treatment 1 intervention
Group B: LY4086940 Dose 2Experimental treatment 1 intervention
Group C: LY4086940 Dose 3, Titration Schedule AExperimental treatment 1 intervention
Group D: LY4086940 Dose 3, Titration Schedule BExperimental treatment 1 intervention
Group E: LY4086940 Dose 4Experimental treatment 1 intervention
Group F: LY4086940 Dose 5Experimental treatment 1 intervention
Group G: LY4086940 Dose 6, Titration Schedule AExperimental treatment 1 intervention
Group H: LY4086940 Dose 6, Titration Schedule BExperimental treatment 1 intervention
Group I: LY4086940 Dose 6, Titration Schedule CExperimental treatment 1 intervention
Group J: PlaceboPlacebo comparator 1 intervention

Trial outcomes

Primary outcomes

1

Percent Change from Baseline in Body Weight

Time frame
Baseline, Week 32

Secondary outcomes

1

Percent Change from Baseline in Body Weight

Time frame
Baseline, Week 48
2

Change from Baseline Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQOL-Lite-CT)

Time frame
Baseline, Week 32, Week 48
3

Pharmacokinetics (PK): Area Under the Curve (AUC) of LY4086940 for One Dosing Interval at Steady State

Time frame
Week 48
4

PK: Maximum Concentration (Cmax) of LY4086940 at Steady State

Time frame
Week 48

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: